Episodes

  • Adapting to Progress: Vorolanib Intravitreal Implant

    Adapting to Progress: Vorolanib Intravitreal Implant
    Jan 16 2025
    The pipeline for the treatment of wet age-related macular degeneration includes therapies that focus on new molecular targets. Carl J. Danzig, MD, FASRS, discusses a tyrosine kinase inhibitor. This activity is supported by an independent medical education grant from Ocular Therapeutix. Click here to view the webinar event, which includes images from the talk. Want to view more education? Click here.
    Show More Show Less
    13 mins
  • Adapting to Progress: Axitinib Intravitreal Implant for Wet AMD

    Adapting to Progress: Axitinib Intravitreal Implant for Wet AMD
    Aug 15 2024
    David Eichenbaum, MD, will discuss the bioresorbable, hydrogel axitinib intravitreal implant that is under investigation in the SOL-1 phase 3 trial for the treatment of neovascular age-related macular degeneration. This activity is supported by an independent medical education grant from Ocular Therapeutix. Click here to view the webinar event, which includes images from the talk. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    11 mins
  • Adapting to Progress: Gene Therapy for nAMD

    Adapting to Progress: Gene Therapy for nAMD
    Aug 15 2024
    Margaret A. Chang, MD, MS, will discuss gene therapies in the pipeline for the treatment of neovascular age-related macular degeneration. This activity is supported by an independent medical education grant from Ocular Therapeutix. Click here to view the webinar event, which includes images from the talk. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    16 mins
  • Adapting to Progress: Evolving nAMD Trials Amid Therapeutic Expansion

    Adapting to Progress: Evolving nAMD Trials Amid Therapeutic Expansion
    Jun 25 2024
    Drs. Dilsher Dhoot and Arshad M. Khanani explain the key aspects of the recently released FDA guidelines for clinical trial design in neovascular age-related macular degeneration and how these changes will influence the interpretation of clinical trial data and the subsequent integration of these therapies into clinical practice. This activity is supported by an independent medical education grant from Ocular Therapeutix. Click here to view the webinar event, which includes images from the talk. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    32 mins
  • Consensus Conversations: Neurotrophic Keratitis: Implementing Best Practices

    Consensus Conversations: Neurotrophic Keratitis: Implementing Best Practices
    Apr 30 2024
    Kendall E. Donaldson, MD, MS and Christopher E. Starr, MD, highlight best practices when treating neurotrophic keratitis, including differential diagnosis, corneal sensitivity testing, the new classification system, treatments options for each stage, and pipeline therapies. This activity is supported by an unrestricted educational grant from Dompé. Click here to view the webinar event, which includes images from the talk. Check out the central hub of this webinar series. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    29 mins
  • Consensus Conversations: Neurotrophic Keratitis: Maintenance Therapy and Investigative Agents

    Consensus Conversations: Neurotrophic Keratitis: Maintenance Therapy and Investigative Agents
    Apr 30 2024
    Drs. Donaldson and Starr delve into cenegermin’s clinical trial data and whether or not it should be used in patients with stage 1 neurotrophic keratitis (NK). They also discuss a handful of investigational agents for treating NK. This activity is supported by an unrestricted educational grant from Dompé. Click here to view the webinar event, which includes images from the talk. Check out the central hub of this webinar series. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    34 mins
  • Consensus Conversations: Treating Stage 1 Neurotrophic Keratitis

    Consensus Conversations: Treating Stage 1 Neurotrophic Keratitis
    Apr 30 2024
    Kendall E. Donaldson, MD, MS and Christopher E. Starr, MD, discuss why it’s important to treat stage 1 neurotrophic keratitis, the treatment options for each stage, and a patient who was treated with multiple therapies. This activity is supported by an unrestricted educational grant from Dompé. Click here to view the webinar event, which includes images from the talk. Check out the central hub of this webinar series. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    23 mins
  • Diabetic Macular Edema

    Diabetic Macular Edema
    Mar 8 2024
    In this case-based discussion focused on diabetic macular edema, Murtaza Adam, MD, FASRS, and Lejla Vajzovic, MD, FASRS, highlight the use of more durable treatment options and how to incorporate these second-generation therapies into the armamentarium. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. Click here to view the webinar event, which includes images from the talk. Check out the central hub of this webinar series. Want to register with Evolve Medical Education? Click here.
    Show More Show Less
    18 mins